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1. Introduction 
Psoriasis is a chronic inflammatory skin disorder affecting 1–3% of the general population 
worldwide. Up to one-third of psoriatic patients have concomitant psoriatic arthritis (Gerdes 
et al, 2009). Multiple studies and clinical trials support an important role for dysregulation 
of the immune system in the development of psoriasis. In recent years, the improved 
understanding of the molecular basis underlying psoriasis has led to the introduction of 
biological drugs, providing a new effective treatment option for this disease. Biologics target 
key steps in the pathogenesis of psoriasis, and can be classified into three main categories: 
TNF inhibitors, T cell inhibitors and IL-12/IL-23 inhibitors (Weger, 2010). In this chapter 
we discuss the state of the art of biological therapies for psoriasis and psoriatic arthritis and 
give a brief overview of the new biological approaches that are currently undergoing 
evaluation for the treatment of both diseases. 
2. TNF Inhibitors 
TNF is a proinflammatory cytokine that plays key roles in both innate and adaptive 
immunity. At high concentrations, it can trigger an excessive inflammatory response ending 
in organ damage. The development of anti-TNF biologics originated from a study by 
Brennan et al., which showed that the expression of pro-inflammatory cytokines by 
synoviocytes in  rheumatoid arthritis patients was inhibited by TNF-neutralizing antibodies 
(Brennan et al, 1989). To date, the role of TNF in psoriasis and psoriatic arthritis has been 
fully investigated (Schottelius et al, 2004). Increased levels of TNF and a differential 
expression of TNF receptors I and II have been found in lesional psoriatic skin compared 
with normal-appearing skin; in addition, in psoriatic patients, the plasma concentration of 
TNF is higher and the mRNA expression of this cytokine is increased in peripheral blood 
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mononuclear cells. Currently, four TNF antagonists are approved for the treatment of 
psoriasis and/or psoriatic arthritis, namely etanercept, infliximab, adalimumab and 
golimumab; a new TNF inhibitor (certolizumab pegol) is currently undergoing a phase III 
trial for the treatment of psoriatic arthritis. 
2.1 Etanercept  
Etanercept is a recombinant human fusion protein consisting of a dimer of the extracellular 
portion of TNF receptor II linked to the Fc portion of IgG1 (Amgen, Inc, 2011). Etanercept 
binds to both the trimeric form of soluble TNF and to the transmembrane form, 
antagonizing their biological actions (Bachmann et al, 2010). Several studies reported a 
reduction of different inflammatory cell types in psoriatic lesions during etanercept 
treatment, such as T cells, natural killer cells, neutrophils, macrophages and plasmocytoid 
dendritic cells (de Groot et al, 2010). Etanercept also blocks downstream T-cell mediated 
events inducing apoptosis of CD11c+ myeloid dendritic cells (Malaviya et al, 2006). In 
addition, etanercept has been shown to down-regulate Th17 cell markers, as well as Th17 
cell products and effector molecules (Antiga et al, 2010; Zaba et al, 2007). Etanercept is FDA- 
and EMA-approved for the treatment of psoriasis and psoriatic arthritis. It is also approved 
for the treatment of other autoimmune conditions such as rheumatoid arthritis, juvenile 
idiopathic arthritis and ankilosing spondilytis (Amgen, Inc., 2011). 
2.1.1 Administration 
Etanercept is administered subcutaneously at a dose of 50 mg twice a week in patients with 
plaque psoriasis or at 25 mg twice a week in patients with psoriatic arthritis during the first 
12 weeks of treatment. After the initiation phase, the dosage for plaque psoriasis is reduced 
to 25 mg twice a week or 50 mg weekly during the maintenance phase (Amgen, Inc., 2011). 
Etanercept can be administered either continuously or intermittently. Gordon et al reported 
no loss of efficacy with intermittent therapy, with a similar response between retreatment 
and initial therapy in psoriatic patients (Gordon et al, 2006a). However, a multicenter 
European open-label study showed that both regimens provide a significant improvement 
in quality of life, with a greater improvement in the continuous treatment group (Dauden et 
al, 2009). Non-neutralizing anti-etanercept antibodies have been observed by several 
authors, but the relevance of them is still debated (Bachmann et al, 2010). 
2.1.2 Clinical efficacy 
Several high-quality clinical trials (Cassano et al, 2010; Gottlieb et al, 2003; Leonardi et al, 
2003, 2010; Papp et al, 2005; Tyring et al, 2007; van de Kerkhof et al, 2008) have evaluated 
both the short-term and long-term efficacy of etanercept in the treatment of psoriasis. In 
clinical trials, the severity of psoriasis is assessed by the Psoriasis Area and Severity Index 
(PASI). PASI 75 is defined as a 75% reduction in PASI score compared with baseline. An 
initial randomized, double-blind, placebo-controlled, multicenter trial of 112 patients 
demonstrated a PASI 75 response in 30% of patients receiving 25 mg etanercept twice a 
week compared with 2% of placebo-treated patients after 12 weeks. After 24 weeks, PASI 75 
response increased to 56% in the etanercept-treated arm compared with 5% in the placebo 
group (Gottlieb et al, 2003). Leonardi et al. demonstrated that the efficacy of etanercept  is 
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dose-related, reporting a PASI 75 response in 34% and 49% of patients treated with 25 mg 
and 50 mg twice weekly after 12 weeks of treatment, respectively. The improvement 
continued through week 24, with 44% and 59% of patients achieving a PASI 75, respectively 
(Leonardi et al, 2003).  The same high-dose etanercept regimen was used in a recent study 
by Griffiths et al., who reported a PASI 75 response in 57% of patients after 12 weeks of 
treatment (Griffiths et al, 2010). In a further multicentre 24-week study, the efficacy of 
etanercept during the initial treatment phase and after dose reduction were evaluated (Papp 
et al, 2005). Patients were treated with a dose of 50 mg etanercept, 25 mg etanercept or 
placebo twice weekly for the first 12 weeks. During the second 12 weeks of treatment, the 
dosage was reduced to 25 mg twice weekly. Papp et al. reported a PASI 75 in 49% of 
patients treated with 50 mg twice weekly and in 34% of patients receiving 25 mg twice 
weekly of etanercept compared with 3% in the placebo group at week 12, and demonstrated 
that the effect obtained with the higher dose could be preserved in most patients after dose 
reduction (Papp et al, 2005). A further increase of the dose of etanercept to 100 mg did not 
demonstrate an improvement in efficacy (Cassano et al, 2006). Recent data by van de 
Kerkhof et al. demonstrated that etanercept 50 mg once weekly for 24 weeks was effective, 
with a PASI 75 response of 38% after 12 weeks, which increased to 71% after 24 weeks 
(van de Kerkhof et al, 2008). Similar results were reported by Sterry et al. (Sterry et al, 
2010). Regarding long-term efficacy, etanercept response has been demonstrated to last up 
to 96 weeks, resulting in a statistically significant improvement (Tyring et al, 2007; 
Esposito et al, 2010). Etanercept is the only biological drug that has shown efficacy and 
safety in pediatric patients with moderate to severe plaque psoriasis (Paller et al, 2008). 
Paller et al. reported a PASI 75 response in 57% of children and adolescents treated with 
etanercept (0.8 mg/kg body weight) compared with 11% in placebo patients after 12 
weeks. The efficacy of the treatment was maintained through 96 weeks (Paller et al, 2010). 
Treatment with etanercept also provides  an improvement in the quality of life of patients, 
as measured by the Dermatology Life Quality Index (DLQI) (Leonardi et al, 2003; van de 
Kerkhof et al, 2008).  
Two pivotal studies have demonstrated the efficacy of etanercept in the treatment of 
psoriatic arthritis. In these studies, the American College of Rheumatology (ACR) criteria is 
the most frequently parameter used to assess the severity of psoriatic arthritis. A double-
blind, placebo-controlled study enrolling 60 patients suffering from psoriatic arthritis 
showed achievement of ACR 20, ACR 50 and ACR 70 response in 73%, 50% and 13% of 
patients after 12 weeks of treatment with etanercept, compared with 13%, 3% and 0% in the 
placebo group (Mease et al, 2000). Furthermore, the same authors reported an additional 
double-blind, placebo-controlled clinical trial in 250 patients with psoriatic arthritis. At 12 
weeks, an ACR 20 response was observed in 59% of etanercept-treated patients compared 
with 15% of the placebo group. This study also reported an improvement in quality of life 
measured by the Health Assessment Questionaire (HAQ) (Mease et al, 2004). The 
improvements observed were maintained for up to 2 years (Mease et al, 2010). A recent 
study by Saougou et al. reported a PASI 90 response in 68% of etanercept-treated patients 
affected by psoriatic arthritis after 5 years (Saougou et al, 2011).   
Although highly effective as monotherapy, few studies have been published on the 
combination of etanercept with cyclosporine, narrowband UVB, acitretin and methotrexate 
(reviewed in Foley et al, 2010). Preliminary data from short-term analysis support the use of 
etanercept in combination therapy which does not seem to be associated with additional 
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toxicities. This provides an attractive option for patients inadequately responding to 
monotherapy. However, further long-term studies are needed to confirm the safety of 
combination therapy.     
2.2 Infliximab 
Infliximab is a chimeric IgG anti-TNF monoclonal antibody constiting of a human constant 
(75%) region and murine variable (25%) regions (Centocor Ortho Biotech, Inc., 2011). In vivo, 
infliximab binds to human TNF and forms stable complexes, resulting in the loss of 
biological activity of this pro-inflammatory cytokine (Scallon et al, 1995). Infliximab is able 
to neutralize both soluble and trans-membrane TNF and induces the elimination of TNF 
bearing cells, such as macrophages, dermal dendritic cells, and T cells (Gisondi et al, 2004; 
Zaba et al, 2007). Recently, it has been suggested that infliximab induces p53-related 
keratinocytes apoptosis, highlighting another effect of this drug in psoriasis (Raho et al, 
2011). Infliximab is FDA- and EMA-approved for the treatment of psoriasis, psoriatic 
arthritis, rheumatoid arthritis, ankylosing spondylitis, adult and pediatric Crohn’s disease 
and ulcerative colitis (Centocor Ortho Biotech, Inc., 2011). 
2.2.1 Administration 
Infliximab is administered as a 2-3 hour intravenous infusion at a dose of 5mg/kg. The 
infusions are given at weeks 0, 2 and 6 (induction period) and then every 8 weeks 
(maintenance period) (Centocor Ortho Biotech, Inc., 2011). The efficacy of continuous 
versus intermittent treatment was evaluated in the clinical trial EXPRESS II, reporting that 
continuous treatment achieved better results than intermittent therapy to maintain PASI 
response and to reduce the occurrence of anti-infliximab antibodies, the most common 
cause of decreased drug efficacy (Haraoui et al, 2006; Menter et al, 2007; Vena & Cassano, 
2007). 
2.2.2 Clinical efficacy 
Several pivotal clinical trials demonstrated the clinical efficacy of infliximab in the treatment 
of plaque psoriasis (Chaudhari et al, 2001; Gottlieb et al, 2004; Reich et al, 2005, 2006). Two 
phase II studies evaluated the efficacy of infliximab at different doses, 5 and 10 mg/kg and 3 
and 5 mg/kg, respectively (Chaudhari et al, 2001; Gottlieb et al, 2004). In the first study of 33 
psoriatic patients, a PASI 75 response was observed in 82% and 73% of patients receiving 5 
and 10 mg/kg of infliximab, respectively, and in 8% of the patients receiving placebo after 
10 weeks. In the second study (SPIRIT) of 249 plaque psoriasis patients,  72% and 88% of 
patients receiving 3 and 5 mg/kg of infliximab, respectively, achieved PASI 75 at week 10 
compared with 6% of the placebo-treated patients. These results demonstrated a high short-
term efficacy of infliximab and identified 5 mg/kg as the ideal dosage regimen in the 
treatment of psoriasis. The rapid response induced by infliximab decreased after 50 weeks 
(Reich et al, 2005). The phase III multi-center, double-blind, placebo-controlled trial 
EXPRESS enrolled 378 patients with plaque psoriasis and showed a PASI 75 response in 80% 
of the patients after 10 weeks compared with 3% in placebo group. The response was 
maintained through week 24 and decreased to 61% by week 50. Nevertheless, the 
retrospective analysis of the EXPRESS trial showed that infliximab continuous therapy for 1 
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year resulted in a sustained improvement in PASI score (Reich et al, 2010). Moreover, 
infliximab provides a substantial improvement in quality of life, with a meaningful decrease 
in DLQI both in short-term and long-term treatment (Feldmann et al, 2005; Gottlieb et al, 
2004; Menter et al, 2007; Reich et al, 2006, 2010).  
The IMPACT trial evaluated the efficacy of infliximab in 104 patients with psoriatic arthritis 
(Antoni et al, 2005a). At week 16, 65% of patients achieved ACR 20 compared with 10% of 
the placebo group and 46% and 29% achieved ACR 50 and ACR 70, respectively. The 
efficacy of infliximab has been evaluated in a larger cohort of patients (n=200) in the 
IMPACT 2 trial. At week 14, 64% of infliximab-treated patients showed a PASI 75 response 
and 58% achieved ACR 20; in addition ACR 20 criteria were maintained up to 1 year 
(Antoni et al,  2005b; Kavanaugh et al, 2007).  The long-term efficacy of infliximab was 
evaluated by a two-year extension of the IMPACT trial (Antoni et al, 2008). At week 98, 
maintenance of the ACR 20 criteria was observed in 68% of infliximab-treated patients and 
64% of them achieved PASI 75. 
Regarding combination therapy, the concomitant administration of methotrexate has been 
reported to prolong the long-term efficacy of infliximab by decreasing the development of 
human anti-infliximab neutralizing antibodies (Klotz et al, 2007).  
2.3 Adalimumab 
Adalimumab is the first fully humanized recombinant anti-TNF monoclonal antibody. 
Adalimumab is able to bind both soluble and membrane-bound TNF in a dose-dependent 
manner (Abbott Laboratories, 2011). It has been shown that adalimumab lyses TNF-
bearing cells in the presence of complement and induces apoptosis in vitro; in addition 
adalimumab affects the biological responses controlled by TNF, such as the expression of 
adhesion molecules, serum concentration of cytokines, reactive oxygen species and dendritic 
cells in psoriatic plaques (Papoutsaki et al, 2007). Moreover, adalimumab is able to modulate 
Toll-like receptors expression on basal keratinocytes (De Pità et al, 2011). Adalimumab is 
FDA- and EMA-approved for the treatment of psoriasis, psoriatic arthritis, rheumatoid 
arthritis, Crohn’s disease, juvenile idiopathic arthritis and ankylosing spondylitis (Abbott 
Laboratories, 2011).    
2.3.1 Administration 
Adalimumab is administered as a subcutaneous injection and the recommended dose for 
psoriasis is a loading dose of 80 mg at week one, followed by 40 mg at week two and 
continuous 40 mg injection every other week (eow) for maintenance. In psoriatic arthritis 
the ideal dosage regimen is 40 mg every second week (Abbott Laboratories, 2011). The 
continuous therapy with adalimumab seems to be more effective than intermitted therapy 
to provide a sustained response (Menter et al, 2008).  Recently, encouraging results have 
been obtained in the retreatment of patients who relapsed after interruption of 
adalimumab therapy (Papp et al, 2011) and patients who lost efficacy during treatment 
with another TNF antagonist (Van et al, 2008). Development of anti-adalimumab 
antibodies may occur, as demonstrated in patients with rheumatoid arthritis (Bartelds et 
al, 2010). 
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2.3.2 Clinical efficacy 
The clinical efficacy of adalimumab was analyzed by three main clinical trials (Gordon et al, 
2006b; Menter et al, 2008; Saurat et al, 2008). In an earlier phase II study enrolling 147 
psoriatic patients, two dose regimens of adalimumab were evaluated. Gordon et al. reported 
a PASI 75 improvement in 80% of patients treated with 40 mg weekly and in 53% of patients 
receiving 40 mg eow compared with 4% of patients in the placebo group at week 12. At 
week 60, PASI 75 response was observed in 64% and 56% of patients treated with 40 mg 
weekly or 40 mg eow, respectively (Gordon et al, 2006b). The phase III placebo-controlled 
randomized trial by Menter et al. of 1212 patients with plaque psoriasis evaluated the 
efficacy of adalimumab 40 mg eow. The authors reported a PASI 75 response rate in 71% of 
the patients after 16 weeks and in 70% after 24 weeks of 40 mg eow adalimumab therapy; 
the efficacy decreased during weeks 33 to 52 (Menter et al, 2008). The first head-to-head trial 
CHAMPION compared adalimumab vs methotrexate and reported a PASI 75 response in 
80% of patients in the adalimumab 40 mg eow group, in 36% of patients in the methotrexate 
group and in 19% of those in the placebo group (Saurat et al, 2008). An improvement in 
DLQI after treatment with adalimumab has been reported by several studies (Menter et al, 
2010; Revicki et al, 2008; Saurat et al, 2008; Shikiar et al, 2007). 
The clinical efficacy of adalimumab in psoriatic arthritis has also been described (Genovese 
et al, 2007; Gladman et al, 2007; Mease et al, 2005, 2009). The ADEPT trial involving 315 
psoriatic arthritis patients tested the long-term clinical efficacy of adalimumab through 2 
years. Mease et al. reported that 58% of patients treated with adalimumab achieved the ACR 
20 after 12 weeks compared with 14% of the patients in the placebo group and that similar 
percentages were maintained up to week 104 (Mease et al, 2005, 2009). These data were 
confirmed by Genovese et al. who reported an ACR 20 response in 65% of adalimumab-
treated patients after week 24 (Genovese et al, 2007). 
Recently, the use of adalimumab in combination with traditional therapies was evaluated in 
psoriasis. Adalimumab with methotrexate results in a lower discontinuation rate of the 
TNF antagonist (Heiberg et al, 2008); the concomitant administration of adalimumab with 
phototherapy seems to be clinically effective, but further investigations in controlled clinical 
trials are needed (Bagel, 2011). The use of topical agents in combination with adalimumab 
results in a higher short-term efficacy that decreases after 4 weeks (Thaçi et al, 2010). 
2.4 Golimumab 
Golimumab is a new TNF antagonist and, like adalimumab, is a fully human anti-TNF 
IgG monoclonal antibody, which binds to both soluble and transmembrane forms of TNF. 
Golimumab has been recently FDA- and EMA-approved for the treatment of psoriatic 
arthritis as monotherapy or in combination with methotrexate. Golimumab is also approved 
for controlling symptoms of rheumatoid arthritis and ankylosing spondylitis (Centocor 
Ortho Biotech, Inc., 2010). 
2.4.1 Administration 
Golimumab is the first patient-administered once-monthly anti-TNF drug. The 
recommended dosage is 50 mg subcutaneously every 4 weeks (Centocor Ortho Biotech, 
Inc., 2010). 
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2.4.2 Clinical efficacy 
The phase III GO-REVEAL clinical trial evaluated the efficacy of golimumab in 405 patients 
suffering from active psoriatic arthritis (Kavanaugh et al, 2009a). Patients received 50 mg, 
100 mg or placebo once every 4 weeks. Achievement of ACR 20 criteria at week 14 was the 
primary end-point and was observed in 51% of patients treated with 50 mg, in 45% of 
patients receiving 100 mg of golimumab and in 9% of patients in the placebo group. At 24 
weeks, Kavanaugh et al. reported further improvement, with 52% and 61% of patients 
treated with 50 mg and 100 mg achieving ACR 20 criteria, respectively, compared with only 
12% of patients in the placebo group. At week 14, a PASI 75 was achieved in 40% and in 58% 
of patients receiving 50 mg and 100 mg golimumab, respectively, compared to 3% of 
patients receiving placebo (Kavanaugh et al, 2009a). Long-term efficacy of golimumab was 
evaluated in a 2-year trial (Kavanaugh et al, 2009b). At week 52, the percentage of patients 
treated with 50 mg of golimumab achieving ACR 20 and PASI 75 responses was 78% and 
62%, respectively. At week 104, the proportion of patients with the aforementioned clinical 
responses increased to 91% and 69%, respectively. With regard to the group of patients who 
received 100 mg of golimumab, Kavanaugh et al. observed an ACR 20 response in 81% and 
in 73% of patients at week 52 and 104, respectively. At the same time points, the percentage 
of patients achieving a PASI 75 was 70% and 76%, respectively (Kavanaugh et al, 2009b). 
The authors also reported an improvement in physical function and quality of life 
(Kavanaugh et al, 2009a). 
2.5 Certolizumab pegol 
Certolizumab Pegol is another TNF antagonist approved for the treatment of rheumatoid 
arthritis and Crohn’s disease (UCB, Inc., 2010). It is a pegylated Fab fragment of a 
humanized anti-TNF antibody. The presence of polyethylene glycol prolongs serum half-
life of the drug. Certolizumab pegol is unable to induce antibody-dependent cell-mediated 
cytotoxicity and complement-dependent cytotoxicity because of the lack of the Fc region 
(Bourne et al, 2008). Preliminary data from two phase II clinical trials showed that 
certolizumab pegol is effective in patients with moderate to severe plaque psoriasis 
(Ortonne et al, 2007, 2008a, 2008b). In these studies the efficacy and safety at two different 
dose regimens were evaluated. Patients were treated with 200 mg, 400 mg of certolizumab 
pegol or placebo every two weeks subcutaneously. At week 12, a PASI 75 response was 
observed in 74.6% of patients receiving 200 mg and in 82.8% of 400 mg treated-patients 
compared with 6.8% of patients in the placebo group (Ortonne et al, 2007). The same authors 
showed that at week 12 a higher number of patients achieved PASI 90 and had a greater 
improvement in health-related quality of life (Ortonne et al, 2008a, 2008b). A phase III trial 
of certolizumab pegol for psoriatic arthritis is ongoing (UCB, Inc., 2010).  
2.6 Safety of TNF inhibitors 
The aforementioned clinical trials show that TNF antagonists are well tolerated and safe. 
The commonest side effect associated with etanercept, adalimumab and golimumab 
treatment is a reaction at the site of injection, including redness, itching, bruising, pain, 
swelling and/or irritation as well as allergic reactions such as latex allergy (Kerbleski & 
Gottlieb, 2011). Treatment with infliximab is associated with infusion reactions, occurring in 
around 20% of patients, including pruritus, headache, rash, urticaria, fever or anaphylactic 
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reactions (Leman & Burden, 2008). For all TNF inhibitors, the primary concern is the 
increased risk for viral, bacterial and fungal infections, mainly of the upper respiratory tract 
(Kunz, 2009). Therapy with anti-TNF agents can lead to reactivation of latent tuberculosis, 
more frequently with infliximab (associated with the highest risk) and adalimumab than 
etanercept (Dixon et al, 2006). Another safety issue is the development of malignancies. The 
use of TNF inhibitors is associated with an increased risk of non-melanoma skin cancer 
(NMSC); the occurence of NMSC may be due to the previous use of phototeraphy and 
immunosuppressive agents, even if a potential risk to develop cancer after anti-
TNFtherapy cannot be excluded (Kerbleski & Gottlieb, 2011). A paradoxical side effect of 
anti-TNF therapies is the new onset and worsening of psoriasis, which have been reported 
in some cases (Ko et al, 2009). Infliximab, adalimumab and golimumab have been shown to 
cause hepatotoxicity (Kavanaugh et al, 2009a; Reich et al, 2005). On the contrary, etanercept 
seems to be effective and safe in the treatment of psoriatic patients with chronic hepatitis C 
virus-infection (Piccolo et al, 2008; Zeinn et al, 2005). Moreover, TNF inhibitors can 
potentially worsen congestive heart failure (Chung et al, 2009). The TNF blockade can lead 
to development of antinuclear antibodies and anti-double-stranded DNA antibodies. A 
lupus-like syndrome may occur with TNF antagonists, but it is a rare event that reverts after 
discontinuation of therapy (Ramos-Casals et al, 2008). Other rare events associated with 
TNF antagonists are the development of serious hematological diseases, such as leukopenia, 
neutropenia, thrombocytopenia, pancytopenia or aplastic anemia and the development or 
worsening of peripheral and central demyelinating disorders (Montane et al, 2007; Roberts 
& McColl, 2004). Rare dermatological diseases such as erythema multiforme, Steven’s 
Johnson syndrome and toxic epidermal necrolysis have been reported during etanercept, 
infliximab and adalimumab treatment (Kerbleski & Gottlieb, 2011).  
3. T-cell inhibitors 
Psoriasis is defined as a T cell-mediated autoimmune disease based on the advanced 
understanding of its pathogenesis. Primarily, a deregulated Th1/Th17 response has been 
reported in psoriatic skin (Lowes et al, 2008). Due to the primary role that T cells play in this 
disease, a new class of biologics has been designed to interfere with T-cell activation and 
functions. Currently, alefacept is the only T cell inhibitor drug approved for the treatment of 
psoriasis. Efalizumab was withdrawn from the market because of the associated risk of 
progressive multifocal leukoencephalopathy. Two other T-cell modulators are currently 
being evaluated for their use in psoriasis and psoriatic arthritis. 
3.1 Alefacept 
Alefacept is a recombinant human fusion protein consisting of the soluble lymphocyte 
function-associated antigen-3 (LFA-3) and the IgG1 Fc fragment (Biogen Inc., 2003). The 
LFA-3 portion binds to CD2, highly expressed on CD4+ and CD8+ memory-effector T cells 
(CD45RO+), while the IgG1 portion binds to Fc receptors on cytotoxic cells (da Silva et al, 
2002). Alefacept inhibits T-cell activation and proliferation, by interfering with the 
downstream activation of cytokines by interfering with the binding between CD2 on T 
lymphocytes and LFA-3 on antigen-presenting cells (da Silva et al, 2002). Since CD2 is 
highly expressed on CD45RO+ T cells, alefacept mainly inhibits memory-effector T cells, 
which represent the majority of T lymphocytes in psoriatic lesions, and preserves naïve cells 
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(Krueger, 2002). Alefacept also causes the depletion of CD45RO+ memory T cells via 
cytotoxic cell-mediated apoptosis; this occurs between CD2 on target T lymphocytes and Fc 
receptors, primarily FcRIII+, on natural killer cells and macrophages (Cooper et al, 2002). 
Alefacept was the first FDA-approved biologic agent in 2003 for the treatment of moderate 
to severe chronic plaque psoriasis in patients who are candidates for systemic treatment or 
phototherapy (Biogen Inc., 2003) but it is not currently approved for the treatment of 
psoriasis by EMA. It is also being investigated for the treatment of other conditions caused 
by T-cell dysregulation, such as psoriatic arthritis (Kraan et al, 2002; Mease & Reich, 2009). 
3.1.1 Administration 
The recommended administration of alefacept is a once-weekly 15 mg intramuscular 
injection (IM) for 12 weeks (Biogen Inc., 2003), although intravenous bolus injection (IV) has 
also been evaluated in several studies. A comparison of the pharmacokinetic and biologic 
activity of IM and IV administration showed that an adequate dose of IM alefacept leads to 
similar bioavailability and efficacy compared to IV administration and it is associated with 
minimal adverse effects (Vaishnaw & TenHoor, 2002). Retreatment with an additional 12-
week course may be initiated if CD4+ T-lymphocyte counts are within the normal range, 
and a minimum of a 12-week interval has passed since the previous course of treatment 
(Biogen Inc., 2003).  
3.1.2 Clinical efficacy 
A series of clinical trials showed significant improvement in the PASI score in patients 
treated with alefacept. The first multicenter, randomized, controlled phase II trial was 
conducted in 229 patients who received alefacept 0.025, 0.075 and 0.150 mg/kg IV or 
placebo weekly for 12 weeks, with a 12-week follow-up (Ellis & Krueger, 2001). Patients 
achieved a reduction in PASI by 38%, 53% and 53%, respectively, compared with 21% 
reduction by placebo. A significant improvement in quality of life was also reported, and 
long-term follow-up showed a sustained response for a median of 10 months (Ellis & 
Krueger, 2001).  
Two phase III clinical trials showed similar results (Krueger et al, 2002; Lebwohl et al, 2003). 
In these trials, patients with chronic plaque psoriasis received a once-weekly administration 
of alefacept IV or IM for 12 weeks, with a 12-week follow-up. In the first study (Krueger et 
al, 2002), a total of 553 patients was randomized to receive 7.5 mg of IV alefacept or placebo, 
while in the second trial (Lebwohl et al, 2003) 507 patients were treated with 10 or 15 mg of 
IM alefacept or placebo. Both trials showed a significant clinical improvement in psoriatic 
patients: a PASI 75 was achieved by 28% in IV-treated patients compared to 8% in placebo-
treated patients, and by 28% and 33% in 10 or 15 mg IM-treated patients, respectively, 
compared to 13% in the placebo group. Most responder patients maintained a 50% or 
greater reduction in PASI in the follow-up period. Other studies have been performed to 
investigate alefacept efficacy and safety in the long-term treatment of plaque psoriasis. 
Treatment of up to 5 courses provided incremental efficacy in responders, while 
maintaining the safety profile (Menter et al, 2006; Roberts et al, 2010). Although these 
studies are limited by the decreasing number of patients over multiple treatment courses or 
the lack of appropriate controls, but do they suggest that multiple courses of alefacept are 
well tolerated and maintain clinical improvement in responder patients.  
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Several studies evaluated the effect of alefacept in combination with other therapies, 
including topical agents, methotrexate, cyclosporine, acitretin, systemic retinoids, or 
phototherapy (Krueger et al, 2008). The results suggest that the combination of alefacept 
with other psoriasis therapies is efficacious and well tolerated but larger studies are needed 
to confirm these results and evaluate long-term effects.  
3.1.3 Safety 
Alefacept is one of the safest biologic drugs for psoriasis. Clinical trials have demonstrated 
that it is well tolerated (Gottlieb, 2004; Krueger et al, 2002; Lebwohl et al, 2003; Roberts et al, 
2010). The main concern is T lymphocyte depletion so that monitoring of CD4+ T cells is 
required during treatment and administration should be withheld if the CD4+ T-cell count 
falls below 250 cells/mL (Biogen Inc., 2003). The most common side effects are pharyngitis, 
headache, rhinitis, bronchitis and flu (Ellis & Krueger, 2001; Gottlieb et al, 2003; Krueger et 
al, 2002; Lowe et al, 2003). These infections are not severe, and there is no evidence to date to 
suggest a predisposition to malignancies associated with alefacept.   
3.2 Abatacept 
Abatacept is a fusion protein composed of an Fc fragment of IgG1 and the extracellular 
domain of CTLA-4 (cytotoxic lymphocyte antigen-4) that inhibits T-cell costimulation. 
Abatacept is currently approved for the treatment of rheumatoid arthritis (Bristol-Myers 
Squibb, 2009). A phase II study has been terminated for psoriatic arthritis and it showed that 
10 mg/kg may be an effective treatment (Mease et al, 2011).   
3.3 Rituximab 
Rituximab is a chimeric monoclonal antibody that selectively binds the CD20 antigen of B 
cells. Rituximab is currently used in the treatment of non Hodgkin’s lymphoma and 
rheumatoid arthritis (Genentech USA, Inc., 2011). A phase I trial is ongoing to assess the 
efficacy and safety of rituximab in patients with psoriatic arthritis (Swedish Medical 
Center, 2009). 
4. IL-12/IL-23 inhibitors 
A third class of biologics classified as IL-12/IL-23 inhibitors has been developed for treating 
psoriasis. These two cytokines, mainly produced by activated dendritic cells, lead to 
differentiation of Th cells into the Th1 and Th17 subsets, respectively (Nestle et al, 2009). 
Moreover, elevated levels of IL-12 and IL-23 have been observed in psoriatic skin lesions 
(Yawalcar et al, 2009). Currently, ustekinumab is FDA- and EMA-approved for the 
treatment of chronic plaque psoriasis, whereas briakinumab, has recently had its approval 
application withdrawn in the US and Europe to conduct further analysis and clinical trials 
(Centocor Ortho Biotech, 2009; Kurzeia et al, 2011).  
4.1 Ustekinumab 
Ustekinumab is a fully human monoclonal antibody that binds to the p40 subunit that is 
shared by IL-12 and IL-23 (Centocor Ortho Biotech, 2009). IL-12 activates natural killer and T 
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cell responses, including CD4+ T cell differentiation toward the Th1 phenotype, while IL-23 
leads to Th17 differentiation, regulates T memory cells, and activates macrophages to 
maintain chronic autoimmune inflammation (Aggarwal et al, 2003; Trinchieri, 2003). 
Ustekinumab prevents the interaction of these cytokines with the IL-12Rǃ1 receptor, 
neutralizing their  immune-mediated responses. A single administration of anti-IL-12p40 
demonstrated significant changes in psoriatic skin lesions after 2 weeks, including the 
reduction of a type 1 cytokine (IFN-) and chemokines (IL-8, IFN--inducible protein-10, and 
MCP-1), and a decrease of TNF and infiltrating T cells (Toichi et al, 2006). 
Ustekinumab was approved by the FDA in September 2009 for the treatment of adult 
patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or 
systemic therapy (Centocor Ortho Biotech, 2009). Early-stage clinical trials have also 
demonstrated its therapeutic potential  in psoriatic arthritis (Gottlieb et al, 2009).  
4.1.1 Administration 
Ustekinumab is administered by subcutaneous injections at the recommended dose of 45 mg 
for patients who weigh ≤100 kg and 90 mg for those who weight ≥100 kg, at week 0 and 
then at week 4, followed by one injection every 12 weeks as maintenance treatment 
(Centocor Ortho Biotech, 2009). Clinical response to ustekinumab is associated with serum 
ustekinumab concentration and patient body weight. Two phase III clinical trials 
demonstrated that efficacy of the 45 and 90 mg doses of ustekinumab was similar in patients 
weighing ≤100 kg, while the 90 mg dose was more effective than the 45 mg dose in patients 
weighing >100 kg (Leonardi et al, 2008; Papp et al, 2008). 
4.1.2 Clinical efficacy 
The first phase II trial was performed in 320 patients with moderate-to-severe plaque 
psoriasis who were randomized to receive one of four subcutaneous dosing regimens of 
ustekinumab (one 45 mg dose, one 90 mg dose, 4-weekly 45 mg doses, or 4-weekly 90 mg 
doses) or placebo (Krueger et al, 2007). At week 12, a PASI 75 was achieved by 52%, 59%, 
67%, and 81%, respectively, of the aforementioned groups, compared to 2% of placebo 
patients. Other measures of clinical outcome, including DLQI and Physician’s Global 
Assessment (PGA) showed significant improvements in responders compared with placebo 
patients at both weeks 12 and 24. Two important clinical trials for the assessment of 
ustekinumab efficacy and safety are PHOENIX-1 and PHOENIX-2. Both are large-scale, 
randomized, placebo-controlled phase III trials designed to evaluate the efficacy and safety 
of ustekinumab in patients with moderate-to-severe plaque psoriasis over a period of five 
years. In the PHOENIX-1 study, 766 patients were randomized to subcutaneous injections of 
45 mg or 90 mg of ustekinumab at weeks 0 and 4 and then every 12 weeks, or placebo at 
weeks 0 and 4, with crossover to ustekinumab at week 12 (Leonardi et al, 2008). At week 12, 
a PASI 75 was achieved by 67.1%, 66.4%, and 3.1% of patients receiving 45 mg, 90 mg or 
placebo, respectively. Results at week 28 demonstrated durable effects of ustekinumab with 
71.2% and 78.6% of patients treated with 45 mg or 90 mg achieving or maintaining a PASI 75 
score. Patients that achieved PASI 75 were re-randomized to maintenance ustekinumab or 
withdrawal from treatment at week 40. A PASI 75 response was better maintained in 
patients receiving maintenance ustekinumab than in those who were withdrawn from 
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treatment. The median time to loss of PASI 75 in patients withdrawn from therapy was 15 
weeks. The PHOENIX-2 study enrolled 1230 patients (Papp et al, 2008). Its design and 
results were similar to the PHOENIX-1 study: a PASI 75 was achieved by 66.7% of patients 
in the 45 mg group, by 75.7% in the 90 mg group, by 3.7% in the placebo group, at week 12. 
However, a dosing intensification was added for those subjects who did not respond fully to 
ustekinumab (PASI 50 to <75). At week 28, partial responders were re-randomized to 
continue dosing regimen every 12 weeks or to increase dosing frequency to every 8 weeks. 
In the 90 mg group, 22 of 33 partial responders achieved PASI 75 after increasing dosage 
frequency to every 8 weeks. Conversely, dosing intensification did not improve clinical 
outcomes in the 45 mg group. The authors concluded that intensification of dosing to once 
every 8 weeks with ustekinumab 90 mg might be necessary to achieve a full response in 
partial responders. The ACCEPT study is a randomized phase III clinical trial that directly 
compares ustekinumab to etanercept in 903 patients with psoriasis (Griffiths et al, 2010). 
Patients were randomized to receive ustekinumab 45 or 90 mg at week 0 and 4, or 
etanercept 50 g twice weekly for 12 weeks. At week 12 PASI 75 was achieved by 74% of the 
patients in the ustekinumab 90 mg group, by 68% of patients in the ustekinumab 45 mg 
group, and by 57% of those in the etanercept group. Patients who were unresponsive to 
etanercept were switched to ustekinumab, with almost a 50% response rate within the first 
12 weeks. There were no significant safety differences between ustekinumab and etanercept 
in the ACCEPT trial. Both drugs were generally well tolerated. This head-to-head 
comparison clearly showed a significant superiority of ustekinumab over etanercept for the 
treatment of patients with moderate-to-severe psoriasis. However, this trial only evaluated 
12 weeks of therapy, a  short period to have an adequate comparison of the drugs, especially 
for their safety profiles.  
4.1.3 Safety 
In general, ustekinumab is well tolerated with only mild adverse events experienced in 
clinical trials. The most common adverse events have been equally observed between the 
treatment and placebo groups and included upper respiratory infections, headache, 
nasopharyngitis, arthralgia, back pain, and injection site reactions (Leonardi et al, 2008; 
Papp et al, 2008). Safety concerns exist for risks of infection and suppression of tumor 
immune surveillance. Individuals congenitally deficient in IL-12p40 or IL-12R1 are known 
to have an increased susceptibility to intracellular pathogens, including tuberculosis and 
salmonella (Döffinger et al, 2002). However, in the PHOENIX 1 and 2 studies only two 
serious infections occurred in the ustekinumab group treated with the 90 mg dose. No 
mycobacterial or salmonella infections were reported. The risk of malignancy did not appear 
to be significant. Cutaneous malignancies were reported in two patients in the PHOENIX 2 
study, a squamous cell carcinoma in the placebo group and a basal cell carcinoma in the 90 
mg treatment group. No malignancies were reported in the PHOENIX 1 trial. The rate of 
malignancies reported in ustekinumab-treated patients was comparable to the rate in the 
general population. Patients with psoriasis have an increased risk of cardiovascular events. 
In the phase II trial of ustekinumab two patients experienced myocardial infarction and one 
suffered a stroke (Krueger et al, 2007). However, subsequent larger phase III studies 
revealed no apparent increased risk of cardiovascular side effects. Further studies are 
needed to assess long-term ustekinumab safety in patients treated for extended periods. 
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4.2 Briakinumab 
Briakinumab is a recombinant fully human IgG1 monoclonal antibody directed against the 
shared p40 subunit of IL-12 and IL-23 (Kimball et al, 2008). Due to its binding to the aforesaid 
cytokines, briakinumab causes a decrease in secretion of IL-6, IL-12, INF- and TNF, as 
demonstrated in patients with Crohn’s disease (Ding et al, 2008). In a phase II study, 180 
patients suffering from psoriasis were treated with placebo or briakinumab at one of the 
following doses: one 200 mg dose at week 0, 100 mg eow for 12 weeks, 200 mg weekly for 4 
weeks, 200 mg eow for 12 weeks, 200 mg weekly for 12 weeks. At week 12, an improvement in 
PASI 75 was reported for all briakinumab-treated groups compared with placebo (Kimball et 
al, 2008). The retreatment efficacy and the long-term safety of briakinumab through 48 weeks 
have been evaluated by the same authors (Kimball et al, 2009). Kimball et al. reported that the 
efficacy of briakinumab was higher in the first 12 weeks compared with the re-treatment 
phase, although more patients showed a PASI 75 response during this period. The most 
frequent adverse events observed during the treatment with briakinumab were injection site 
reactions, upper respiratory infections and nasopharyngitis. 
5. Perspectives 
In the last decade, the detailed comprehension of the molecular mechanisms involved in 
psoriasis has led to the development of new biological drugs, such as monoclonal 
antibodies, recombinant proteins and small RNA drugs, which are currently under 
evaluation for psoriasis and/or psoriatic arthritis. 
5.1 Anti-interleukin 17 
IL-17 is a pro-inflammatory cytokine produced by Th17 T cells, one of the key players  in the 
pathogenesis of psoriasis. Due to its role in psoriasis, IL-17 is a new emerging target for 
biological therapy.  
AMG 827 is a fully human IgG2 anti IL-17 receptor monoclonal antibody investigated in 
phase II trials for psoriasis, rheumatoid arthritis and Crohn’s disease (Amgen, 2011). 
Preliminary data from a small study showed that psoriatic patients treated with 700 mg 
AMG 827 IV had a significant improvement in terms of histopathological features and PASI 
score (Russell et al, 2010). 
AIN457 is a recombinant fully human anti-IL-17 monoclonal antibody that selectively binds 
and neutralizes IL-17. The efficacy and safety of AIN457 has been evaluated in a phase II 
trial (Jancin, 2009) which enrolled 36 patients suffering from chronic plaque psoriasis. A 
PASI 75 response was observed in 44% of patients receiving 3 mg/kg AIN457 IV compared 
with 9% of placebo group. AIN457 is currently undergoing phase II studies for psoriasis, 
psoriatic arthritis and rheumatoid arthritis and a phase III study for uveitis (Novartis, 2010).  
LY2439821 is a new humanized IgG4 anti-IL-17 monoclonal antibody in a phase II trial for 
psoriasis and rheumatoid arthritis (Eli Lilly and Company, 2011).    
5.2 Anti-interleukin 22 
IL-22 is a pro-inflammatory cytokine produced by both Th17 and a new group of T cells 
known as Th22 cells; Th22 cells are known to induce epidermal hyperplasia and dermal 
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inflammation via several transcription factors such as STAT3 (Nograles et al, 2009). ILV-094 
is a fully human anti IL-22 monoclonal antibody. A phase I study to evaluate the efficacy 
and safety of ILV-094 in psoriasis has been recently completed, while it is currently ongoing 
a phase II trial for rheumatoid arthritis  (Pfizer, 2010). 
5.3 Chaperonin 10 
Chaperonin 10 belongs to the heat shock proteins family and acts as a molecular chaperon, 
regulating protein folding. Several studies support its anti-inflammatory activity and its role 
in down-regulating the excessive immune response (van Eden, 2008). Recombinant 
Chaperonin 10 (Cpn10) mimics these activities and its efficacy in psoriasis has been 
evaluated by a single-center, double-blind exploratory study, showing a significant 
improvement in Cpn10-treated patients (Williams et al, 2008). Phase II trials have been 
completed for psoriasis, rheumatoid arthritis and multiple sclerosis (Golant & Gutman-
Yassky, 2011).  
5.4 Small RNA drugs 
The use of RNA interference as a drug is one of the possible therapeutic strategies to target 
the pro-inflammatory cytokines involved in psoriasis, as shown by several phase I and II 
ongoing clinical trials (reviewed in Jackson et al, 2006). On the basis of their role in psoriasis, 
suitable mRNA targets are TNF, IL-20 and IL-23. A recent study showed that local small 
RNA therapy against TNF provided amelioration in psoriasis in a xenograft 
transplantation model (Jakobsen et al, 2009). These results indicate that RNA interference is 
a potential therapy in the treatment of inflammatory skin diseases. Nevertheless the main 
challenge for this kind of therapy remains the delivery of small RNA.  
6. Conclusion 
The introduction of biological drugs in clinical practice has revolutionized the treatment of 
psoriasis and psoriatic arthritis in the last decade. Biologics have shown to be effective and 
to have an acceptable safety profile, but there is still a need to assess long-term toxicity 
through clinical experience and careful post-marketing surveillance.  
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